J
Junyuan Wang
Researcher at Pfizer
Publications - 2
Citations - 440
Junyuan Wang is an academic researcher from Pfizer. The author has contributed to research in topics: Bosutinib & Chronic myelogenous leukemia. The author has an hindex of 2, co-authored 2 publications receiving 405 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes,Hagop M. Kantarjian,Tim H. Brümmendorf,Dong-Wook Kim,Anna G. Turkina,Zhi Xiang Shen,Ricardo Pasquini,H. Jean Khoury,Steven Arkin,Angela Volkert,Nadine Besson,Richat Abbas,Junyuan Wang,Eric Leip,Carlo Gambacorti-Passerini +14 more
TL;DR: Data suggest bosutinib is effective and tolerable in patients with chronic phase imatinib-resistant or imatinIB-intolerant CML, and responses were seen across Bcr-Abl mutants, except T315I.
Journal ArticleDOI
An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Carlo Gambacorti-Passerini,Dong-Wook Kim,Hagop M. Kantarjian,Tim H. Brümmendorf,Irina Dyagil,Laimonas Griskevicius,Hemant Malhotra,Yeow-Tee Goh,Junyuan Wang,Karin Gogat,Jorge E. Cortes +10 more
TL;DR: A randomized, open-label, phase 3 study compared the activity and safety of bosutinib with that of imatinib in newly diagnosed patients with CP CML, suggesting good efficacy and an overall favorable safety profile.